Opportunities and challenges for biosimilars: What's on the horizon in the global insulin market?

Clinical Diabetes

Volumn 30, Issue 4, 2012, Pages 138-150

  Rotenstein, Lisa S ^a   Ran, Nina ^b   Shivers, Joseph P ^c   Yarchoan, Mark ^d   Close, Kelly L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Close Concerns ^*  (United States)

^c SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; EXENDIN 4; GENERIC DRUG; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL EDUCATION; DIABETES MELLITUS; DRUG APPROVAL; DRUG COST; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; FINANCIAL MANAGEMENT; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; MANAGED CARE ORGANIZATION; NOCTURNAL HYPOGLYCEMIA; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; WEIGHT GAIN;

EID: 84871639510     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.4.138     Document Type: Article

References (86)

1. Diabetes drug and device industry 1Q12 financial model. San Francisco, Calif., Close Concerns, Inc., 2012
2. Herbst KL, Hirsch IB: Insulin strategies for primary care providers. Clinical Diabetes 20:11-17, 2002
3. Joshi SR, Parikh RM, Das AK: Insulin history, biochemistry, physiology and pharmacology. Pharmacology 55:19-25, 2007
4. Hirsch IB: Insulin analogues. N Engl J Med 352:174-183, 2005
5. Little S, Shaw J, Home P: Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 13 (Suppl. 1):S53-S64, 2011
6. Garber AJ, Ligthelm R, Christiansen JS, Liebl A: Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 9:630-639, 2007
7. Agency for Healthcare Research and Quality: Premixed Insulin for Type 2 Diabetes: A Guide for Young Adults. [Publication Number 08(09)-EHC017-A] Rockville, Md., Agency for Healthcare Research and Quality, 2009
8. Novo Nordisk: First three months of 2012 investor presentation in London [article online]. Available from http://webmedia.novonordisk.com/nncom/images/investors/investor_presentations/2012/IR_presentations/Q1_2012_Investor_presentation_London.pdf. Accessed 28 June 2012
9. Heinemann L: Biosimilar insulins. Expert Opin Biol Ther 12:1009-1016, 2012
10. U.S. Food and Drug Administration: Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Rockville, Md., Food and Drug Administration, 2012
11. Home P: Biosimilars: risks and benefits. Presentation at the 2nd Latin American Congress on Controversies in Diabetes, Obesity, and Hypertension, 23-25 March 2012, Rio de Janeiro, Brazil
12. International Diabetes Federation: Healthcare expenditures [article online]. Available from http://www.idf.org/diabetesatlas/5e/healthcare-expenditures. Accessed 17 June 2012
13. Shivers JP, Brown AS, Yarchoan M, Chang EM, Kozak BM, Wu VL, Rotenstein LS, Hirsch IB, Wood R, Close KL: Patient and educator attitudes toward biosimilar insulin. Poster presentation (1225-P) at the 72nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, Philadelphia, Pa.
14. Strom B: Generic drug substitution revisited. N Engl J Med 316:1456-1462, 1987
15. Mason J, Bearden W: Generic drugs: consumer, pharmacist, and physician perceptions of the issues. J Consum Aff 14:193-207, 1980
16. Shrank WH, Cox ER, Fischer MA, Joytsna MA, Choudry N: Patients' perceptions of generic medicines. Health Aff 28:546-556, 2009
17. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudry NK: Physician perceptions about generic drugs. Ann Pharmacother 45:31-38, 2011
18. Lewek P, Kardas P: Generic drugs: the benefits and risks of making the switch. J Fam Pract 59:634-640, 2010
19. U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation: Expanding the use of generic drugs [article online]. Available from http://aspe.hhs.gov/sp/reports/2010/GenericDrugs/ib.shtml. Accessed 28 June 2012
20. U.S. Food and Drug Administration: Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Rockville, Md., U.S. Food and Drug Administration, 2012
21. Home P: Biosimilar. Diabetes Voice 56:40-43, 2011
22. Schellekens H: Assessing the bioequivalence of biosimilars: the retacrit case. Drug Discov Today 14:9-10, 2009
23. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS: Immunological responses to exogenous insulin. Endocr Rev 28:625-652, 2007
24. Kramer I: The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Brit J Diabetes Vasc Dis 12:163-171, 2010
25. Home P: Biosimilars. Presentation at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, Calif.
26. European Medicines Agency: Guidance on Similar Medicinal Products Containing Recombinant Human Soluble Insulin. London, European Medicines Agency, 2006
27. World Health Organization: Guidelines on Evaluation of Similar Biotherapeutic Products. Geneva, Switzerland, World Health Organization, 2009
28. U.S. Food and Drug Administration: Guidance for Industry Regarding Implementation of the Guidance for Industry Biosimilars: Questions and Answers. Rockville, Md., U.S. Food and Drug Administration, 2012
29. Class JN, Langis L: A patient-centered paradigm for the biosimilars market. Communications 1:17-21, 2012
30. Keeping K: Biosimilar opportunity within the insulin market. Presentation at GTCbio 2nd Annual Diabetes Summit, 19-20 April 2012, Boston, Mass.
31. Haag T, Krattiger C: The emergence of biosimilars: how are they different from generics and what are the implications for marketing? Presentation at the European Pharmaceutical Market Research Association's 2011 Conference, 27-29 June 2011, Basel, Switzerland
32. Biologics Price Competition and Innovation Act of 2009 in the Patient Protection and Affordable Care Act (Public Law 111-148). Washington, D.C., 2010. Available from http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/content-detail.html. Accessed 10 August 2012
33. Grabowski H, Long G, Mortimer R: Implementation of the biosimilars pathway: economic and policy issues. Seton Hall Law Review 41:511-557, 2011
34. Kopenski F: Understanding biosimilars and projecting the cost savings to employers. Milliman Publications [article online]. Available from www.insight.milliman.com/article.php?cntid=8063. Accessed 19 June 2012
35. Myers BE: Managed Care Perspectives on Biosimilars. Thesis presented at University of Alaska at Anchorage, 2011
36. Carroll J: Payers begin to make plans for coming wave of biosimilars [article online]. Available from http://www.managedcaremag.com/archives/1006/1006.regulation.html. Accessed 18 June 2012
37. Rodwin MA: Medical education and physician prescribing: a historical review and reform proposal. J Law Med Ethics 38:807-815, 2010
38. Waxman H: The lessons of Vioxx: drug safety and sales. N Engl J Med 352:2576-2578, 2005
39. Liang BA, Mackey T: Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity. Ther Clin Risk Manag 7:489-493, 2011
40. Chatterji A, Hisey RT, Jacoby R, Hoffman T: The follow-on biologics market: enter at your own risk, 2011 [article online]. Available from http://ssrn.com/abstract=1969973. Accessed 20 June 2012
41. Generics and Biosimilars Initiative: Questions over U.S. biosimilars pathway in light of Teva's BLA [article online]. Available from http://www.gabionline.net/Biosimilars/General/Questions-over-US-biosimilarspathway-in-light-of-Teva-s-BLA. Accessed 19 June 2012
42. Sekhon BS, Saluja V: Biosimilars: an overview. Biosimilars 1:1-11, 2011
43. Selam J-L: Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4:505-513, 2010
44. Eli Lilly: Lilly Cares [Web site]. Available from www.lillytruassist.com/pages/aboutlillycares.aspx. Accessed 19 June 2012
45. Novo Nordisk: Cornerstones4Care [Web site]. Available from http://www.cornerstones4care.com/ToolsResources/PatientAssistance.aspx. Accessed 19 June 2012
46. Sanofi: Sanofi Patient Connection [Web site]. Available from http://patientassistanceprogram.sanofi-aventis.us
47. Grabowski H, Cockburn I, Long G: The market for follow-on biologics: how will it evolve? Health Aff 5:1291-1301, 2006
48. Rao SK: Pricing biologics: issues, strategic priorities and a conceptual model. J Commer Biotechnol 14:7-23, 2010
49. World Health Organization international nonproprietary names [article online]. Available from http://www.who.int/medicines/services/inn/en. Accessed 18 June 2012
50. U.S. Food and Drug Administration public hearing on approval pathway for biosimilar and interchangeable biological products. Silver Spring, Md., 11 May 2012
51. Declerck P: Biologicals in the era of biosimilars: implications for naming and prescribing. J Eur Assoc Hosp Pharm 13:51-53, 2007
52. Rader R: Nomenclature of new biosimilars will be highly controversial. Bioprocess Int 9:26-33, 2011
53. Joshi SR: Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 59 (Suppl.):3-6, 2011
54. Hoadley J: Cost Containment Strategies for Prescription Drugs: Assessing the Evidence in the Literature. Menlo Park, Calif., Kaiser Family Foundation, 2005
55. Aschner P: Biosimilarity: does it matter? Presentation at the 2nd Latin American Congress on Controversies in Diabetes, Obesity, and Hypertension, 23-25 March 2012, Rio de Janeiro, Brazil
56. Kelly C, Mir F: Economics of biological therapies. BMJ 339:666-669, 2009
57. Dranitsaris G, Amir E, Dorward K: Biosimilars of biological drug therapies: regulatory, clinical, and commercial considerations. Drugs 71:1-10, 2011
58. Biocon Limited: Biocon Limited announces earnings for the half year ended September 30, 2011 [article online]. Available from www.biocon.com/biocon_inv_press_releases_20102011. Accessed 18 June 2012
59. Sanofi: Sanofi first quarter 2012 press release: strong performance in Q1 2012 including Genzyme contribution [article online]. Available from http://en.sanofi.com/Images/30273_20120427_Q1-2012-results_en.pdf. Accessed 28 June 2012
60. Sanofi: Sanofi iBGStar blood glucose monitoring system now available in the U.S [article online]. Available from http://sanofi.mediaroom.com/index.php?s=43&item=358. Accessed 19 June 2012
61. Sanofi: Sanofi strategy and outlook IR thematic seminar transcript [article online]. Available from http://en.sanofi.com/images/28716_2011-09-06_IR_them_seminar_presentation.pdf. Accessed 20 June 2012
62. Amylin Pharmaceuticals: Byetta approved for use with insulin glargine in the U.S. [article online]. Available from http://amln.client.shareholder.com/releasedetail.cfm?ReleaseID=655118. Accessed 19 June 2012
63. Amylin Pharmaceuticals: FDA approves Bydureon: the first and only once-weekly treatment for type 2 diabetes [article online]. Available from http://amln.client.shareholder.com/releasedetail.cfm?releaseid=655097. Accessed 19 June 2012
64. Novo Nordisk: Victoza label in the U.S. updated to include data showing superior efficacy when compared to Januvia [article online]. Available from http://www.novonordisk.com/press/sea/sea.asp?sShowNewsItemGUID=4260e411-5022-443a-99f2-23383a802b58&sShowLanguageCode=en-GB. Accessed 19 June 2012
65. ORIGIN Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328, 2012
66. Sanofi: Apidra for kids [article online]. Available from http://www.apidra.com/apidra/for-kids.aspx. Accessed 19 June 2012
67. Sanofi: Sanofi Q411 earnings call [Webcast online]. Available from http://en.sanofi.com/investors/events/corporate/2012/2012-02-08_Results_2011.aspx. Accessed 19 June 2012
68. Zealand Pharma: Zealand Pharma annual report 2011 [article online]. Available from http://ir.zealandpharma.com/common/download/download.cfm?companyid=ABEA-58QR0J&fileid=558227&filekey=07155554-4c3b-498f-82aa-9732c666092d&filename=UK_REPORT_2011_final.pdf. Accessed 19 June 2012
69. dQ&A Market Research: DQ&A Panel Q4 2010 Summary Report. dQ&A Market Research, San Francisco, Calif., 2010
70. Eli Lilly: Update for insulin pump use provides an additional option for children with type 1 diabetes and extends amount of time people can use and store Humalog insulin in their pumps [article online]. Available from http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=583437. Accessed 18 June 2012
71. Fierce Pharma: Lilly nabs co-branded insulin deal with Walmart [article online]. Available from http://www.fiercepharma.com/story/lilly-nabs-co-branded-insulin-dealwalmart/2010-06-23. Accessed 18 June 2012
72. Eli Lilly: Lilly Clinical Development Pipeline [Web site]. Available from http://www.lilly.com/SiteCollectionDocuments/Pipeline/ClinicalDevelopmentPipeline/index.html. Accessed 18 June 2012
73. Eli Lilly: Eli Lilly Investment Community Meeting [Webcast online]. Available from http://investor.lilly.com/eventdetail.cfm?eventid=89214. Accessed 18 June 2012
74. Eli Lilly: Eli Lilly & Co Q12012 Earnings Call [Webcast online]. Available from http://investor.lilly.com/eventdetail.cfm?eventid=99681. Accessed 18 June 2012
75. nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, Philadelphia, Pa.
76. Rosenstock J, Bergenstal RM, Blevins T, Morrow L, Prince M, Qu Y, Sinha VP, Howey DC, Jacober SJ: Better glycemic control and weight loss with the novel longacting basal insulin LY2605541 compared with insulin glargine in patients with type 1 diabetes. Poster presentation (1026-P) at the 72nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, Philadelphia, Pa.
77. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals J: Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycemic control in T1D and T2D. Poster presentation (1023-P) at the American Diabetes Association 72nd Scientific Sessions, 8-12 June 2012, Philadelphia, Pa.
78. Boehringer Ingelheim: Boehringer Ingelheim and Lilly's new type 2 diabetes treatment Tradjenta (linagliptin) tablets for adults now available in U.S. pharmacies [article online]. Available from http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2011/june_15_2011.html. Accessed 18 June 2012
79. Novo Nordisk: Form 20-F/A, 2011 [article online]. Available from http://sec.gov/Archives/edgar/data/353278/000120864612000037/c106165.htm. Accessed 20 June 2012.
80. Novo Nordisk: FDA approves Levemir pregnancy category change for women with diabetes [article online]. Available from http://press.novonordisk-us.com/index.php?s=43&item=320. Accessed 18 June 2012
81. Novo Nordisk: FDA approves Levemir for expanded use in children two to five years of age with type 1 diabetes [article online]. Available from http://press.novonordisk-us.com/index.php?s=43&item=331. Accessed 18 June 2012
82. Meneghini L, Atkin S, Bain S, Blonde L, Raz I, Begtrup K, Johansen T, Birkeland KI: Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes. Poster presentation (35-LB) at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, Calif.
83. st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, Calif.
84. Heller S: Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes. Oral presentation (70-OR) at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, Calif.
85. st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego, Calif.
86. Novo Nordisk: Novo Nordisk R&D Pipeline [Web site]. Available from http://www.novonordisk.com/science/pipeline/rd_pipeline.asp. Accessed 18 June 2012